Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terlipressin after EVL in acute variceal hemorrhage
NCT06027970Phase 3Unknown
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Sep 2023
- Primary completion
- Aug 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Variceal hemorrhage (VH) comparing Terlipressin Group with Placebo Group (2 arms). Primary endpoints: Re-bleed at 7 days and Mortality at 7 days. Status: unknown.
02
Drugs
terlipressin
03
Conditions
Variceal hemorrhage (VH)
Beyond the preview
Go deeper on NCT06027970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06027970.